{"id":531479,"date":"2021-08-25T16:33:07","date_gmt":"2021-08-25T20:33:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/"},"modified":"2021-08-25T16:33:07","modified_gmt":"2021-08-25T20:33:07","slug":"marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/","title":{"rendered":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignl { text-align: left }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignl\"><b>Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences<\/b><\/p>\n<p>RADNOR, Pa.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.marinuspharma.com%2F&amp;esheet=52481863&amp;newsitemid=20210825005670&amp;lan=en-US&amp;anchor=Marinus+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=1972b7ae6d9254e82ce4f68638dc5826\">Marinus Pharmaceuticals, Inc<\/a>. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that members of its leadership team will present at the following investor conferences in September. The company will also be hosting a virtual R&amp;D Day where it will provide a clinical update and commercial overview on its pipeline programs. More details are below.\n<\/p>\n<p><span class=\"bwuline\">Morgan Stanley 19th Annual Global Healthcare Conference<\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDate and Time: Thursday, September 9, 3:30 PM ET\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nSpeakers: Scott Braunstein, M.D., Chief Executive Officer and Steven Pfanstiel, Chief Financial Officer\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nWebcast Link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmorganstanley.webcasts.com%2Fstarthere.jsp%3Fei%3D1488865%26tp_key%3D6fecae296b&amp;esheet=52481863&amp;newsitemid=20210825005670&amp;lan=en-US&amp;anchor=https%3A%2F%2Fmorganstanley.webcasts.com%2Fstarthere.jsp%3Fei%3D1488865%26amp%3Btp_key%3D6fecae296b&amp;index=2&amp;md5=c03bafad6a30971cf8fba36cff79202c\">https:\/\/morganstanley.webcasts.com\/starthere.jsp?ei=1488865&amp;tp_key=6fecae296b<\/a><\/li>\n<\/ul>\n<p><span class=\"bwuline\">H.C. Wainwright 23rd Annual Global Investment Conference <\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDate and Time: Available on demand starting Monday, September 13, 7:00 AM ET\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nSpeakers: Joe Hulihan, M.D., Chief Medical Officer and Steven Pfanstiel, Chief Financial Officer\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nWebcast Link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjourney.ct.events%2Fview%2F11e7f627-1798-46a2-bf90-a375890833ed&amp;esheet=52481863&amp;newsitemid=20210825005670&amp;lan=en-US&amp;anchor=https%3A%2F%2Fjourney.ct.events%2Fview%2F11e7f627-1798-46a2-bf90-a375890833ed&amp;index=3&amp;md5=8944aa11f19eb4681e035b211097c68f\">https:\/\/journey.ct.events\/view\/11e7f627-1798-46a2-bf90-a375890833ed <\/a><\/li>\n<\/ul>\n<p><span class=\"bwuline\">Baird&#8217;s 2021 Global Healthcare Conference<\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDate and Time: Wednesday, September 15, 3:45 PM ET\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nSpeakers: Joe Hulihan, M.D., Chief Medical Officer and Steven Pfanstiel, Chief Financial Officer\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nWebcast Link: Presentation available to registered clients only\n<\/li>\n<\/ul>\n<p><span class=\"bwuline\">Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit<\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDate and Time: Monday, September 20, 2:05 PM ET\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nSpeakers: Scott Braunstein, M.D., Chief Executive Officer and Steven Pfanstiel, Chief Financial Officer\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nWebcast Link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__wsw.com_webcast_oppenheimer16_mrns_2816864%26d%3DDwQFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DPR4eJhVvGS4Nm3Q3XYDduQpZiJ7CGpeAjMz-NjUPwq4%26m%3Dr703cqkQy_oAmYOfNR7sa-dzmZzQhwvweVMi2cLKRsg%26s%3DzR8vhoDONR_YQ9REGXh3WwckcHYLSvTX1HhBgjoXAiQ%26e%3D&amp;esheet=52481863&amp;newsitemid=20210825005670&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwsw.com%2Fwebcast%2Foppenheimer16%2Fmrns%2F2816864&amp;index=4&amp;md5=3bac2c9faed9d044cb67928760bc665a\">https:\/\/wsw.com\/webcast\/oppenheimer16\/mrns\/2816864<\/a><\/li>\n<\/ul>\n<p><span class=\"bwuline\">2021 Cantor Virtual Global Healthcare Conference<\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDate and Time: Thursday, September 30, 12:00 PM ET\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nSpeakers: Scott Braunstein, M.D., Chief Executive Officer and Steven Pfanstiel, Chief Financial Officer\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nWebcast Link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fcantor12%2Fmari%2F2075290&amp;esheet=52481863&amp;newsitemid=20210825005670&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwsw.com%2Fwebcast%2Fcantor12%2Fmari%2F2075290&amp;index=5&amp;md5=eec6e9f1d3a5813f0546b26ba4adf98b\">https:\/\/wsw.com\/webcast\/cantor12\/mari\/2075290<\/a><\/li>\n<\/ul>\n<p><span class=\"bwuline\">Marinus Virtual R&amp;D Day: Current and Future Pipeline Discussion <\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nWill provide clinical and reformulation updates, discuss new indications, and give a commercial overview on its pipeline programs\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nDate and Time: Tuesday, October 5, 9:00 AM &#8211; 12:00 PM ET\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nWebcast Link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fcc%2Fmrns2%2Fregister.aspx%3Fconf%3Dcc%26page%3Dmrns2%26url%3Dhttps%3A%2F%2Fwsw.com%2Fwebcast%2Fcc%2Fmrns2%2F1446444&amp;esheet=52481863&amp;newsitemid=20210825005670&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwsw.com%2Fwebcast%2Fcc%2Fmrns2%2Fregister.aspx%3Fconf%3Dcc%26amp%3Bpage%3Dmrns2%26amp%3Burl%3Dhttps%3A%2F%2Fwsw.com%2Fwebcast%2Fcc%2Fmrns2%2F1446444&amp;index=6&amp;md5=8ca585621f6d786b0b144bbc908e0a9a\">https:\/\/wsw.com\/webcast\/cc\/mrns2\/register.aspx?conf=cc&amp;page=mrns2&amp;url=https:\/\/wsw.com\/webcast\/cc\/mrns2\/1446444<\/a><\/li>\n<\/ul>\n<p>\nAll of the above public webcasts may be accessed through the <i>Events &amp; Presentations<\/i> page of the <i>Investors &amp; Media<\/i> section of the Marinus website, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.marinuspharma.com&amp;esheet=52481863&amp;newsitemid=20210825005670&amp;lan=en-US&amp;anchor=www.marinuspharma.com&amp;index=7&amp;md5=bba783bb02063d45a51678d7a13afb60\">www.marinuspharma.com<\/a>.\n<\/p>\n<p><b>About Marinus Pharmaceuticals<\/b><\/p>\n<p>\nMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA<sub>A<\/sub> receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year, is planning to conduct a Phase 3 trial in tuberous sclerosis complex, and a Phase 3 trial in refractory status epilepticus is ongoing. For more information visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.marinuspharma.com&amp;esheet=52481863&amp;newsitemid=20210825005670&amp;lan=en-US&amp;anchor=www.marinuspharma.com&amp;index=8&amp;md5=ab4afa222c32e094a51270ab54ff84be\">www.marinuspharma.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210825005670\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210825005670\/en\/<\/a><\/span><\/p>\n<p>\nSasha Damouni Ellis<br \/>\n<br \/>Vice President, Corporate Affairs &amp; Investor Relations<br \/>\n<br \/>Marinus Pharmaceuticals, Inc.<br \/>\n<br \/>484-253-6792<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:sdamouni@marinuspharma.com\">sdamouni@marinuspharma.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Pennsylvania<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Pharmaceutical Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210825005670\/en\/1186982\/3\/FINAL_MARINUS_LOGO_USE_ON_ALL_MATERIALS_%282%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that members of its leadership team will present at the following investor conferences in September. The company will also be hosting a virtual R&amp;D Day where it will provide a clinical update and commercial overview on its pipeline programs. More details are below. Morgan Stanley 19th Annual Global Healthcare Conference Date and Time: Thursday, September 9, 3:30 PM ET Speakers: Scott Braunstein, M.D., Chief Executive Officer and Steven Pfanstiel, Chief Financial Officer Webcast Link: https:\/\/morganstanley.webcasts.com\/starthere.jsp?ei=1488865&amp;tp_key=6fecae296b H.C. Wainwright 23rd Annual Global Investment Conference Date and Time: Available on demand &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-531479","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that members of its leadership team will present at the following investor conferences in September. The company will also be hosting a virtual R&amp;D Day where it will provide a clinical update and commercial overview on its pipeline programs. More details are below. Morgan Stanley 19th Annual Global Healthcare Conference Date and Time: Thursday, September 9, 3:30 PM ET Speakers: Scott Braunstein, M.D., Chief Executive Officer and Steven Pfanstiel, Chief Financial Officer Webcast Link: https:\/\/morganstanley.webcasts.com\/starthere.jsp?ei=1488865&amp;tp_key=6fecae296b H.C. Wainwright 23rd Annual Global Investment Conference Date and Time: Available on demand &hellip; Continue reading &quot;Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-25T20:33:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences\",\"datePublished\":\"2021-08-25T20:33:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/\"},\"wordCount\":536,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/\",\"name\":\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-08-25T20:33:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk","og_description":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that members of its leadership team will present at the following investor conferences in September. The company will also be hosting a virtual R&amp;D Day where it will provide a clinical update and commercial overview on its pipeline programs. More details are below. Morgan Stanley 19th Annual Global Healthcare Conference Date and Time: Thursday, September 9, 3:30 PM ET Speakers: Scott Braunstein, M.D., Chief Executive Officer and Steven Pfanstiel, Chief Financial Officer Webcast Link: https:\/\/morganstanley.webcasts.com\/starthere.jsp?ei=1488865&amp;tp_key=6fecae296b H.C. Wainwright 23rd Annual Global Investment Conference Date and Time: Available on demand &hellip; Continue reading \"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-25T20:33:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences","datePublished":"2021-08-25T20:33:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/"},"wordCount":536,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/","name":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-08-25T20:33:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210825005670r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/531479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=531479"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/531479\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=531479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=531479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=531479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}